Thrivent Financial For Lutherans Ultragenyx Pharmaceutical Inc. Transaction History

Thrivent Financial For Lutherans

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$37.35 - $52.15 $69,508 - $97,051	-1,861 Reduced 4.67%	37,950 $1.75 Million
Q1 2023 May 17, 2023	BUY	$36.99 - $48.71 $104,496 - $137,605	2,825 Added 7.64%	39,811 $1.6 Million
Q4 2022 Feb 08, 2023	SELL	$33.72 - $46.33 $387,206 - $532,007	-11,483 Reduced 23.69%	36,986 $1.71 Million
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $458,860 - $759,485	11,483 Added 31.05%	48,469 $2.01 Million
Q2 2022 Aug 16, 2022	BUY	$45.8 - $85.4 $1.69 Million - $3.16 Million	36,986 New	36,986 $2.21 Million
Q1 2022 May 13, 2022	SELL	$62.2 - $84.4 $1.29 Million - $1.75 Million	-20,757 Closed	0 $0
Q4 2021 Feb 16, 2022	BUY	$73.71 - $87.86 $1.53 Million - $1.82 Million	20,757 New	20,757 $1.75 Million
Q2 2018 Aug 14, 2018	SELL	$48.54 - $85.31 $427,200 - $750,813	-8,801 Closed	0 $0
Q1 2018 May 08, 2018	BUY	$44.33 - $58.52 $390,148 - $515,034	8,801 New	8,801 $449,000

325

85.5M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.01B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.